Summary - ATNF - NASDAQ - Weiss Ratings

E

180 Life Sciences Corp. ATNF

$1.10 $0.03022.81% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$0.6578 - $17.75

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Biotechnology Health Care Pharmaceutical

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

180 Life Sciences Corp. Announces Notice of Allowance for U.S. ...

5/1/2025 - GuruFocus

180 Life Sciences (ATNF) Secures Patent Approval for POCD Treatment Method ATNF Stock News

5/1/2025 - GuruFocus

180 Life Sciences Corp. Announces Notice of Allowance for U.S. ...

5/1/2025 - GuruFocus

180 Life Sciences announces notice of allowance for U.S. patent

5/1/2025 - The Fly

180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction

5/1/2025 - Accesswire

180 Life Sciences Corp. Announces Share Repurchase

4/30/2025 - GuruFocus

180 Life Sciences (ATNF) Streamlines Capital Structure with Share Repurchase ATNF Stock News

4/30/2025 - GuruFocus

180 Life Sciences (ATNF) Restructures Capital with Share Repurchase Agreement ATNF Stock News

4/30/2025 - GuruFocus

180 Life Sciences to repurchase 1.32M shares from Elray for $1M

4/30/2025 - Seeking Alpha - Healthcare

180 Life Sciences to repurchase 1.32M shares from Elray for $1M

4/30/2025 - The Fly

180 Life Sciences Corp. Announces Share Repurchase ATNF Stock News

4/30/2025 - GuruFocus

180 Life Sciences enters settlement, mutual release agreement with Elray, Luxor

4/30/2025 - The Fly

180 Life Sciences Corp. Announces Share Repurchase

4/30/2025 - Accesswire

Weiss Ratings Reiterates "Sell (E+)" Rating for 180 Life Sciences (NASDAQ:ATNF)

2/21/2025 - Ticker Report

Anson Funds Management LP Acquires Shares in 180 Life Sciences Corp

2/15/2025 - GuruFocus

180 Life Sciences Appoints New CEO Amid Leadership Changes

2/7/2025 - TipRanks Financial Blog

180 Life Sciences (NASDAQ:ATNF) Earns "Sell (E+)" Rating from Weiss Ratings

2/4/2025 - Ticker Report

Weiss Ratings Reaffirms Sell (E+) Rating for 180 Life Sciences (NASDAQ:ATNF)

1/20/2025 - Ticker Report

180 Life Sciences Announces Key Proposals and Director Elections

12/31/2024 - TipRanks Financial Blog

180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 148.1% in December

12/29/2024 - Ticker Report

180 Life Sciences Corp. Announces Pricing of $2. ...

12/27/2024 - GuruFocus

180 Life Sciences announces pricing of $2.9M registered direct offering

12/27/2024 - SeekingAlpha.com: All News

180 Life Sciences announces pricing of $2.9M registered direct offering

12/27/2024 - Seeking Alpha - Healthcare

180 Life Sciences prices $2.9M registered direct offering at $2.41 per share

12/27/2024 - TipRanks Financial Blog

Income Statement

Total Revenue (TTM)

--

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

--

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Monday, March 31, 2025

Period Date

Tuesday, December 31, 2024

Next Filing

Week of May 12 and 16 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Apr 09, 2025 - $0.6578

52-week High

Oct 16, 2024 - $17.75

Valuation

Market Cap

$5.56M - Nano Cap

Enterprise Value

Price/Sales (TTM)

--

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

180lifesciences.com

Phone Number

650 285 2387

Address

Building 4
Suite 200 - 3000 El Camino Real
Palo Alto, CA 94306

Country

Year Founded

--

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory... more